4.4 Review

Examining the Metastatic Niche: Targeting the Microenvironment

Journal

SEMINARS IN ONCOLOGY
Volume 37, Issue 5, Pages S2-S14

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminoncol.2010.10.007

Keywords

-

Categories

Funding

  1. Novartis Pharmaceuticals Corporation
  2. Amgen Inc
  3. Roche Diagnostic Corporation

Ask authors/readers for more resources

Some of the most common cancer types, including breast cancer, prostate cancer, and lung cancer, show a predilection to metastasize to bone. The molecular basis of this preferential growth of cancer cells in the bone microenvironment has been an area of active investigation. Although the precise molecular mechanisms underlying this process remain to be elucidated, it is now increasingly being recognized that the unique characteristics of the bone niche provide homing signals to cancer cells, and create a microenvironment conducive for the cancer cells to colonize. Concomitantly, cancer cells release several regulatory factors that result in abnormal bone destruction and/or formation. This complex bidirectional interplay between tumor cells and bone microenvironment establishes a vicious cycle that leads to a selective growth advantage for the cancer cells. The molecular insights gained on the underpinnings of bone metastasis in recent years have also provided us with avenues to devise innovative approaches for therapeutic intervention. The goal of this review is to describe our current understanding of molecular pathophysiology of cancer metastases to bone, as well as its therapeutic implications. Semin Oncol 37 (Suppl 2):S2-S14. (C) 2010 Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available